| 1. |
- Chavez-Rodriguez, Mauro F., et al.
(author)
-
Fuel saving strategies in the Andes : long-term impacts for Peru, Colombia and Ecuador
- 2018
-
In: Energy Strategy Reviews. - : Elsevier. - 2211-467X .- 2211-4688. ; 20, s. 35-48
-
Journal article (peer-reviewed)abstract
- Crude oil exports and imports play a crucial role in the trade balance of Peru, Colombia and Ecuador. These countries are looking into fossil fuel saving measures as a way to deal with increasing demands and decreasing oil production rates. However, studies about the long-term effects of these measures is lacking. Using a combination of energy simulation technics, 17 fuel saving strategies ranging from fuel switching to the investment in underground transport and hydropower capacity expansion were modelled and assessed to evaluate their long-term effect on fossil fuels demand reduction. Our results show that the full implementation of strategies can account for cumulative oil savings of over 550 million barrels of oil by 2030. Findings also point out that Ecuador and Colombia could face the transition from net oil-exporters to importers as soon as the end of the next decade.
|
|
| 2. |
- Vora, Suhani, et al.
(author)
-
Rational design of a compact CRISPR-Cas9 activator for AAV-mediated delivery
- 2018
-
Other publication (other academic/artistic)abstract
- Akin to Zinc Finger and Transcription Activator Like Effector based transcriptional modulators, nuclease-null CRISPR-Cas9 provides a groundbreaking programmable DNA binding platform, begetting an arsenal of targetable regulators for transcriptional and epigenetic perturbation, by either directly tethering, or recruiting, transcription enhancing effectors to either component of the Cas9/guide RNA complex. Application of these programmable regulators is now gaining traction for the modulation of disease-causing genes or activation of therapeutic genes, in vivo. Adeno-Associated Virus (AAV) is an optimal delivery vehicle for in vivo delivery of such regulators to adult somatic tissue, due to the efficacy of viral delivery with minimal concerns about immunogenicity or integration. However, present Cas9 activator systems are notably beyond the packaging capacity of a single AAV delivery vector capsid. Here, we engineer a compact CRISPR-Cas9 activator for convenient AAV-mediated delivery. We validate efficacy of the CRISPR-Cas9 transcriptional activation using AAV delivery in several cell lines.
|
|
